Claims for Patent: 11,491,169

Summary for Patent: 11,491,169

Title:	Remdesivir treatment methods
Abstract:	Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
Inventor(s):	Tomas Cihlar
Assignee:	Gilead Sciences Inc
Application Number:	US17/676,920
Patent Claims:	1. A method of treating a viral infection in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of a compound of Formula Ia, or a pharmaceutically acceptable salt thereof: wherein the human is not being treated with chloroquine, or an analog or salt thereof, thereby treating the viral infection. 2. The method of claim 1, wherein the viral infection is caused by SARS-CoV-2. 3. The method of claim 1, wherein the compound of Formula Ia, or a pharmaceutically acceptable salt thereof is administered intravenously. 4. The method of claim 1, comprising administering to the human the therapeutically effective amount of the compound of Formula Ia: 5. The method of claim 1, wherein the chloroquine, or an analog or salt thereof, is chloroquine, desethylchloroquine, hydroxychloroquine, desethylhydroxychloroquine, or bidesethylhydroxychloroquine, or a pharmaceutically acceptable salt thereof. 6. The method of claim 5, wherein the chloroquine, or an analog or salt thereof, is chloroquine, or a pharmaceutically acceptable salt thereof. 7. The method of claim 6, wherein the chloroquine, or an analog or salt thereof, is chloroquine phosphate. 8. The method of claim 5, wherein the chloroquine, or an analog or salt thereof, is hydroxychloroquine, or a pharmaceutically acceptable salt thereof. 9. The method of claim 8, wherein the chloroquine, or an analog or salt thereof, is hydroxychloroquine sulfate. 10. The method of claim 1, wherein the human weighs at least 40 kg, and the compound of Formula Ia, or a pharmaceutically acceptable salt thereof, is administered intravenously in the first dose of 200 mg on day 1, and administered intravenously in a second dose of 100 mg on each of the following 4 days. 11. The method of claim 10, wherein the second dose of 100 mg is administered for an additional 1 to 5 days. 12. The method of claim 10, wherein the human weighs at least 40 kg, and the compound of Formula Ia, or a pharmaceutically acceptable salt thereof, is administered intravenously in the first dose of 200 mg on day 1, and administered intravenously in a second dose of 100 mg on each of the following 9 days. 13. The method of claim 1, wherein the human weighs from 3.5 kg to less than 40 kg, and the compound of Formula Ia, or a pharmaceutically acceptable salt thereof, is administered intravenously in the first dose of 5 mg/kg on day 1, and administered intravenously in a second dose of 2.5 mg/kg on each of the following 4 days. 14. The method of claim 13, wherein the second dose of 2.5 mg/kg is administered for an additional 1 to 5 days. 15. The method of claim 13, wherein the human weighs from 3.5 kg to less than 40 kg, and the compound of Formula Ia, or a pharmaceutically acceptable salt thereof, is administered intravenously in the first dose of 5 mg/kg on day 1, and administered intravenously in a second dose of 2.5 mg/kg on each of the following 9 days. 16. The method of claim 1, wherein the compound of Formula Ia, or a pharmaceutically acceptable salt thereof, is administered intravenously over from about 30 to about 120 minutes. 17. The method of claim 1, wherein the human has not been administered chloroquine, or an analog or salt thereof, within 1 day of receiving a first dose of the compound of Formula Ia, or pharmaceutically acceptable salt thereof. 18. The method of claim 1, wherein the human has not been administered chloroquine, or an analog or salt thereof, within 10 days of receiving the first dose of the compound of Formula Ia, or pharmaceutically acceptable salt thereof. 19. The method of claim 1, wherein the human has not been administered chloroquine, or an analog or salt thereof, within 90 days of receiving the first dose of the compound of Formula Ia, or pharmaceutically acceptable salt thereof. 20. The method of claim 1, wherein the human has not been administered chloroquine, or an analog or salt thereof, within 365 days of receiving the first dose of the compound of Formula Ia, or pharmaceutically acceptable salt thereof. 21. The method of claim 1, wherein the human is not administered chloroquine, or an analog or salt thereof, during the treatment of the viral infection. 22. The method of claim 1, further comprising instructing the human not to take chloroquine, or an analog or salt thereof, during the treatment of the viral infection. 23. The method of claim 1, further comprising instructing the human to wait at least 10 days after taking chloroquine, or an analog or salt thereof, before administering the compound of Formula Ia, or pharmaceutically acceptable salt thereof. 24. The method of claim 1, wherein the human has a plasma or blood concentration of the chloroquine, or an analog or salt thereof, of less than 50 ng/mL at the time a first dose of the compound of Formula Ia, or pharmaceutically acceptable salt thereof, is administered to the human.